Info

CyGene, Inc. is a biotechnology company based in Ft. Lauderdale, Florida. The Company was originally established in 1995 to develop and commercialize a next generation DNA technology for in-vitro diagnostics. Since then, the Company has developed a tool chest of over 34 fully integrated patented technologies that provide automated detection of virtually any substance in minute quantities based on specified targets such as DNA, RNA, cells, proteins, toxins or chemicals. CyGene's technology base may have a revolutionary impact on a variety of industries. Diagnostics is the critical front-end to the entire medical process. Current in-vitro diagnostics are used to identify advanced stage symptomatic diseases. Late stage disease treatment is highly inefficient and expensive. Cost increases for healthcare have an increasing impact on our economy and are becoming an ever-greater burden to bear as the baby boom generation advances in age. Improved pre-symptomatic disease detection and screening for disease pre-dispositions promise dramatic cost reductions, increased employee productivity and higher success rates for drug therapies. Emerging diseases in the veterinary sector, such as antibiotic resistant strains of tuberculosis, foot and mouth disease and species variants of "mad cow disease" are dealt with extreme measures due to the technical and cost limitations of the current state of technology. Water treatment plants "over process" and treat municipal water supplies due to the complex, expensive and inaccurate quality testing methods. Aside from the human diagnostics sector, for which many applications require regulatory approval through the FDA, there are tremendous market opportunities in less regulated and unregulated markets.